CTLA4 and neoplasm: By releasing immune checkpoint blockage such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), and the programmed cell death protein 1 (PD-1) and its ligand (PD-L1), anti-tumor immune responses can be reactivated.